{"url_path":"/sec/rna/8-k/2026-05-14/item-2-02","section_key":"item-2-02","section_title":"Item 2.02 Results of Operations and Financial Condition.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/2093101/0001193125-26-224238-index.html","accession_number":"0001193125-26-224238","cik":"0002093101","ticker":"RNA","issuer_name":"Atrium Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/2093101/0001193125-26-224238-index.html","primary_entity_key":"0002093101","primary_entity_name":"Atrium Therapeutics, Inc."},"word_count":133,"has_tables":true,"body_markdown":"Item 2.02 Results of Operations and Financial Condition.\n\nOn May 14, 2026, Atrium Therapeutics, Inc. announced its financial results for the quarter ended March 31, 2026. The full text of the press release issued in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.\n\nThe information in this Item 2.02 of this Form 8-K, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing."}